Pliant Therapeutics (PLRX) Operating Income (2019 - 2026)

Pliant Therapeutics (PLRX) has reported Operating Income for 8 consecutive years, with -$23.9 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, Operating Income rose 47.66% year-over-year to -$23.9 million in Q2 2026; TTM through Jun 2026 was -$97.5 million, a 55.66% increase from a year earlier, with the FY2025 full-year figure at -$156.4 million, up 31.52% from the prior year.
• Operating Income was -$23.9 million for Q2 2026 at Pliant Therapeutics, down from -$21.8 million in the prior quarter.
• Over five years, Operating Income peaked at -$21.8 million in Q1 2026 and troughed at -$62.0 million in Q3 2024.
• A 5-year average of -$41.2 million and a median of -$43.8 million in 2023 frame the typical range for Operating Income.
• Across the five-year window, Operating Income sank 59.67% in 2023 and soared 63.06% in 2026, its largest moves.
• Over 5 years, Operating Income stood at -$37.4 million in 2022, then retreated by 25.77% to -$47.0 million in 2023, then slipped by 13.36% to -$53.3 million in 2024, then surged by 55.78% to -$23.6 million in 2025, then retreated by 1.21% to -$23.9 million in 2026.
• The last three Operating Income figures came in at -$23.9 million (Q2 2026), -$21.8 million (Q1 2026), and -$23.6 million (Q4 2025), per Business Quant data.